Plus Therapeutics Partners with Humana for CNSide® Coverage
In an exciting development for oncology diagnostics, CNSide Diagnostics, LLC, part of Plus Therapeutics, Inc. (Nasdaq: PSTV), has entered into a significant national agreement with Humana, Inc. This collaboration aims to provide the CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) laboratory-developed test (LDT) to approximately 16 million individuals across the United States.
This comprehensive coverage agreement, effective from late October, amplifies the total policy coverage for the CNSide CSF TCE LDT to an impressive 67 million people, paving the way for enhanced diagnostic capabilities in the fight against central nervous system (CNS) cancers.
CNSide® CSF Assay: A Breakthrough in Cancer Diagnosis
The CNSide® CSF Assay Platform is a groundbreaking tool that facilitates rapid diagnosis, treatment monitoring, and guidance for patients facing leptomeningeal metastases. The assay's clinical utility has been validated through nine peer-reviewed publications and is supported by promising results from the FORESEE clinical trial, alongside real-world applications in numerous cancer cases.
Since 2020, more than 11,000 CNSide® tests have been conducted at over 120 cancer institutions in the U.S. The test boasts impressive sensitivity of 92% and specificity of 95%, significantly influencing treatment decisions in 90% of cases. Such statistics underscore the test's potential to improve patient outcomes in challenging cancer diagnoses.
Exclusive Access and Services
The CNSide® test is exclusively available through CNSide Diagnostics, LLC, providing healthcare professionals in the U.S. with a vital resource to better manage their patients' treatment plans. This exclusivity showcases their commitment to advancing cancer diagnostics and improving therapeutic strategies.
About CNSide Diagnostics, LLC
CNSide Diagnostics is a wholly owned subsidiary of Plus Therapeutics, Inc., dedicated to developing and commercializing proprietary laboratory-developed tests. Their flagship CNSide® test is specifically designed to identify cancer cells that have spread to the central nervous system in patients with various types of carcinomas and melanomas. This innovative platform facilitates a quantitative analysis of cerebrospinal fluid, enhancing the management of patients suffering from leptomeningeal metastases.
Information on Plus Therapeutics
Plus Therapeutics, headquartered in Houston, Texas, is a clinical-stage pharmaceutical enterprise focused on creating targeted radiotherapeutics for challenging cancers affecting the central nervous system. Their innovative approach combines local beta radiation and targeted drug delivery to enhance clinical outcomes for patients. The company's product pipeline primarily addresses leptomeningeal metastases (LM) and recurrent glioblastoma (GBM), showcasing their commitment to tackling some of the most difficult cases in oncology.
Understanding Humana's Commitment
Humana Inc. is dedicated to putting health first, serving millions of customers through their insurance and health care services. Their comprehensive approach aims to improve the quality of life for individuals across different demographics, including those utilizing Medicare and Medicaid. This partnership with Plus Therapeutics emphasizes Humana's commitment to enhancing health outcomes through innovative solutions and services.
Frequently Asked Questions
What is the CNSide® CSF Assay?
The CNSide® CSF Assay is a laboratory-developed test that enumerates tumor cells in cerebrospinal fluid to assist in the diagnosis and monitoring of metastatic CNS cancer.
Who can access the CNSide® test?
The CNSide® test is available exclusively to healthcare professionals in the U.S. through CNSide Diagnostics, LLC.
How does the CNSide® test improve cancer treatment?
The test provides high sensitivity and specificity, influencing treatment decisions in the majority of cases, thereby enhancing patient management and outcomes.
What impact does the agreement with Humana have?
This agreement offers coverage to approximately 16 million additional individuals, increasing awareness and accessibility of the CNSide® test for patients in need.
What advancements is Plus Therapeutics pursuing?
Plus Therapeutics is developing targeted radiotherapeutics for difficult-to-treat CNS cancers, focusing on improving clinical outcomes through innovative therapies.
